Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
Stay informed about the most active stocks in the S&P500 index on Friday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Stay informed about the most active stocks in the S&P500 index on Thursday's session. Discover the stocks that are generating the highest trading volume and driving market activity.
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Medication company Viatris (NASDAQ:VTRS) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 11.2% year on year to $3.25 billion. The company’s full-year revenue guidance of $13.75 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.50 per share was in line with analysts’ consensus estimates.
The company raised its full-year revenue guidance to between $975 million and $1.025 billion, up from its previous guidance of between $300 million and $350 million.
The pharmaceutical company’s therapies protecting against and treating Covid-19 are less crucial as the pandemic ebbs, and further products will also eventually be open to competition.
Looking for the most active stocks in the S&P500 index on Tuesday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Animal health company Zoetis (NYSE:ZTS) reported Q1 CY2025 results topping the market’s revenue expectations, with sales up 1.4% year on year to $2.22 billion. The company’s full-year revenue guidance of $9.5 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $1.48 per share was 5.8% above analysts’ consensus estimates.
President Donald Trump signed an executive order Monday directing the FDA to accelerate approvals for domestic pharmaceutical manufacturing facilities as his administration prepares to announce new tariffs on imported medicines within two weeks
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
